Live feed07:30:00·1318dPRReleasevia QuantisnowRhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023ByQuantisnow·Wall Street's wire, on your screen.RYTM· Rhythm Pharmaceuticals Inc.Health Care
